Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.
about
Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesisRequirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesisSignaling pathways activated by oncogenic forms of Abl tyrosine kinase.Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatmentp53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells.p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.Chronic myeloid leukemia: mechanisms of blastic transformationTransformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.Modeling Philadelphia chromosome positive leukemias.MicroRNA miR-125b causes leukemiaBCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability.High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia.A requirement for NF-kappaB activation in Bcr-Abl-mediated transformationHigh levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiationA novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.Src kinase signaling in leukaemiaSrc kinases as targets for B cell acute lymphoblastic leukaemia therapy.BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.Benzene-induced hematopoietic neoplasms including myeloid leukemia in Trp53-deficient C57BL/6 and C3H/He mice.BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.Genetic mechanisms of chronic myeloid leukemia blastic transformation.Management of advanced-phase chronic myeloid leukemia.A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation.BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
P2860
Q30168802-6A02FF5F-745F-4399-B213-17B77C7186CDQ30175784-AB4C4421-B7D6-4B93-9172-211243D14FEEQ30439716-433D1FE1-5533-4B98-B4AA-A6A4B3D16E3EQ33663180-D641E94E-EA24-41FE-B95F-DB21E79FFF72Q33887799-AD013D1A-EB71-4936-AB27-3A5B7DF05662Q33958575-A1C6654A-2E83-4855-94C6-F927FD0B08F2Q33961551-F4A30C7F-0CB6-4A4F-8F80-235D0F617982Q33968037-4E740F21-1C04-4789-AB0D-024587745E10Q34250223-5011656A-F642-488E-9437-6790FC036D98Q34281241-75662284-3DA3-46AD-9918-C05B55109C65Q34405446-EF150154-ECC4-4666-A5ED-83437C53921EQ34411303-6060A124-20B3-489E-B15F-7D5AFBA96EEDQ35022527-B2F73871-F1DE-470C-AA91-5353779BAF34Q35104353-DF347741-5D31-4D0D-A738-07F4C38999E4Q35195588-48F45EC9-3D04-4E0A-BE8E-274C28E3058EQ35901685-805345CB-9B4C-479E-BEE4-7F5AB5C9E2B8Q36080675-E34DE9DF-6863-46DE-8241-75EA0A298015Q36116937-CD195517-95D9-47EF-A1A7-D78181DF226FQ36150854-D297F595-00D7-4052-99EC-FFC4CFF932D7Q36323612-FF5C94BF-E459-4DC3-A5A2-3307833470A0Q37256614-31898DAB-6971-4918-8F63-73340663D59CQ37836928-E119D40A-FF68-4D41-B719-76FBF32B3DD0Q37983490-26E30D2C-9B48-41EF-B79F-C818DD18159EQ38452040-1CE4BCCE-4DB1-4D4C-A3D1-93D5DBC2A94AQ40350288-CA4A3015-0418-4E49-B8B0-8D2255622BAAQ40837798-8FBD023D-94D2-4030-9E26-94C6B46534BAQ42126174-97870153-0816-430A-8B4F-EF185C20888BQ50864357-30435C21-AE8A-4526-9A2B-00859B02B3C9
P2860
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.
@ast
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.
@en
type
label
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.
@ast
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.
@en
prefLabel
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.
@ast
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.
@en
P2093
P2860
P356
P1476
Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase
@en
P2093
B Calabretta
D Perrotti
M Nieborowska-Skorska
R Martinez
P2860
P304
13137-13142
P356
10.1073/PNAS.93.23.13137
P407
P577
1996-11-01T00:00:00Z